Acetylcysteine in Bronchiectasis.

Phase 2

Recruiting

• Conditions: bronchiectasis; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12621001013853
• Lead Sponsor: Western Health Foundation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-08-04
• Last Update Posted: 10 August 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

bronchiectasis

Exclusion Criteria

current smokers, those with greater than 20 pack year history, cystic fibrosis, non tuberculous mycobacterial infection.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
sputum neutrophil elastase [Baseline, 3 and 6 weeks]

Secondary Outcome Measures

Name	Time	Method
lung function assessed by spirometry[Baseline and 6 weeks];quality of life as assessed by the Bronchiectasis Quality of Life Questionnaire[baseline and 6 weeks];Adverse effects assessed direct questioning from a checklist developed for this study.Possible side effects include dyspepsia, reflux abdominal discomfort, [baseline, 3 and 6 weeks];Sputum MUC5B[Baseline, 3 and 6 weeks];Sputum IL8[Baseline, 3 and 6 weeks];Dyspnoea assessed by the modified Medical Research Council scale [ Baseline and 6 weeks]